Inactive Instrument

Annidis Corporation Stock

Equities

RHA.H

CA03589A1003

Advanced Medical Equipment & Technology

Dynamic Chart
Annidis Corporation Announces Executive Resignations CI
Annidis Corporation Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2017 CI
Annidis Corporation Announces Unaudited Consolidated Financial Results for the Second Quarter and Six Months Ended June 30, 2017 CI
Annidis Corporation Announces Audited Consolidated Earnings Results for the First Quarter Ended March 31, 2017 CI
Annidis Corporation Announces Audited Consolidated Earnings Results for the Twelve Months Ended December 31, 2016 CI
Annidis Corporation Announces Executive Changes CI
Annidis Corporation announced that it expects to receive CAD 2.18 million in funding CI
Annidis Corporation Announces Private Placement of $500,000 Promissory Note CI
Annidis Corporation Reports Unaudited Consolidated Earnings Results for the Second Quarter Ended June 30, 2016 CI
Annidis Corporation Announces the Resignation of Michael Mueller as Board of Director CI
Annidis Corporation announced that it has received CAD 0.5 million in funding from Mistarunited Technology Co., Limited CI
Annidis Corporation Announces Private Placement of $221,000 Promissory Note CI
Annidis Corporation announced that it has received CAD 0.22 million in funding from Mistarunited Technology Co., Limited CI
Annidis Corporation Auditor Raises 'Going Concern' Doubt CI
Annidis Corporation Announces Management Changes CI
More news
Annidis Corporation develops and markets imaging technologies to eye care professionals. The Company has developed a multi-spectral imaging (MSI) system for retinal and choroidal assessment (the RHA). The RHA provides eye-care professionals with a screening tool for early detection and diagnosis of a range of pathologies. The RHA is an ocular pathology management system that integrates MSI with analytic software and management of ocular pathologies, such as glaucoma, age-related macular degeneration and diabetic retinopathy. Its RHA collects and combines multi-spectral information. The RHA is a non-invasive instrument that uses MSI to take pictures of the retinal layers of eye. The images are then processed using the RHA Report software to reveal various layers in the back of the eye. The Company is also engaged in developing RHA Platinum, which is under development with beta units in clinical testing that allows doctors to visualize choroidal and retinal vasculature non-invasively.
More about the company